Factory 99% Crizotinib Powder CAS 877399-52-5 Anti-Cancer Crizotinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A295
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Crizotinib
• CAS: 877399-52-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Crizotinib
Appearance	White Powder
CAS NO.	877399-52-5
Molecular Formula	C21H22Cl2FN5O
Storage	Keep in a cool, dry, dark location

 

Crizotinib is an ATP-competitive, multi-targeted tyrosine kinase inhibitor developed byPfizer. It selectively inhibits the activity of c-Met, ALK, and ROS1 kinases, which are often abnormally activated in various types of cancer.

 

 

1. Cancer Treatment: Crizotinib is primarily used for the treatment of advanced non-small cell lung cancer (NSCLC) that harbors ALK or ROS1 rearrangements, as well as certain types of metastatic cancer involving c-Met activation.
2. Clinical Trials: It is being evaluated in clinical trials for its potential efficacy in treating other solid tumors and in combination with other therapeutic agents.
3. Personalized Medicine: Genetic testing is often conducted to identify patients with specific genetic alterations (such as ALK, ROS1, or c-Met rearrangements) who are likely to benefit from Crizotinib treatment.

1. Kinase Inhibition: Crizotinib binds to and inhibits the kinase activity of c-Met, ALK, and ROS1, thereby blocking their downstream signaling pathways.
2. Antiproliferative Effects: By inhibiting these kinases, Crizotinib disrupts the abnormal signaling that drives cancer cell proliferation and survival, leading to growth arrest and apoptosis of cancer cells.
3. Improvement of Patient Outcomes: In clinical practice, Crizotinib has demonstrated significant clinical efficacy in improving progression-free survival and overall survival in patients with ALK- or ROS1-positive NSCLC, as well as in those with certain c-Met-driven cancers.